Atlas FDA

PD-L1 IHC 22C3 pharmDX

FDA premarket approval P150013/S020 · decided 2020-11-13

Approval details

PMA number
P150013
Supplement
S020
Supplement type
Panel Track
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
PD-L1 IHC 22C3 pharmDX
Generic name
Immunohistochemistry assay, antibody, programmed death-ligand 1
Applicant
Agilent Technologies, Inc.
Date received
2020-06-29
Decision date
2020-11-13
Days to decision
137 days
Decision code
APPR
Product code
PLS
Advisory committee
Pathology
Expedited review
No
Location
Santa Clara, CA
Statement
Approval for the PD-L1 IHC 22C3 pharmDX for expanding the indications to include detection of PD-L1 protein in patients with triple-negative breast cancer (TNBC) for treatment with KEYTRUDA.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
GenetiSure Dx Postnatal Assay (K163367)Agilent Technologies, Inc.2017-08-11
MODIFICATION TO DEVICE LINK SYSTEM, MODEL M2376A (K012094)Agilent Technologies, Inc.2001-07-20
AGILENT M2636B TELEMON B MONITOR (TELEMON B) (K011824)Agilent Technologies, Inc.2001-07-02
HEARTSTREAM XL DEFIBIBRILLATOR/MONITOR, MODEL M4735A, HEARTSTREAM XLT DEFIBRILLATOR/MONITOR.MODEL M2500B (K010634)Agilent Technologies, Inc.2001-06-11
M2376A DEVICELINK SYSTEM, MODEL M2376A (K011578)Agilent Technologies, Inc.2001-06-08
HEARTSTREAM ATTENUATED DEFIBRILLATION PADS, MODEL M3870A (K003819)Agilent Technologies, Inc.2001-05-02
AGILENT INFORMATION CENTER SOFTWARE FOR M3150,M3151,M3153 AND M3154 (K011093)Agilent Technologies, Inc.2001-05-01
M2376A DEVICELINK SYSTEM (K010453)Agilent Technologies, Inc.2001-03-02